Surrozen (SRZN)
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Surrozen Analyst Rating
View moreForecast & Rating
Oct 2, 2026Price forecast
$48.4065.08%
Forecast & RatingStrong buy
6analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 23 hours ago
Surrozen Initiated with Buy as IND Clearance, New Capital and External Wnt Validation Strengthen Clinical Momentum
- PUBT · 1 day ago, 12:00 PM
Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial
- Global Report · Sep 30 at 10:14 AM
Litigation, Battery Launches and Biotech Research Drive Small-Cap Week
- Weekly Review · Sep 26 at 07:07 AM
Weekly Recap | Surrozen +78.49%, closing in on record highs
